Regenxbio (RGNX) Misses Q2 EPS by 47c, misses on revenue

Regenxbio (NASDAQ: RGNX) reported Q2 EPS of ($1.66), $0.47 worse than the analyst estimate of ($1.19). Revenue for the quarter came in at $19.97 million versus the consensus estimate of $34.5 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.

You May Also Be Interested In

• Regenxbio Inc. (RGNX) PT Lowered to $23 at H.C. Wainwright
• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c